Lisa Rojkjaer - 17 Feb 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Medical Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 17:06:07 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rojkjaer Lisa EVP, Chief Medical Officer RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey (Attorney-in-Fact) 19 Feb 2026 0001846460

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +18,894 +118% $0.000000 34,853 17 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.